Loading patent…
AssigneeORCA Therapeutics B.V.
InventorsWenliang Dong, Tanja Denise De Gruijl, Marta López González, Victor Willem Van Beusechem
Estimating the term…
The invention in one aspect relates to recombinant replication competent adenovirus that can replicate in and lyse a host cell comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence. It also relates, among others, to means and methods for treatment of cancer with a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, preferably in the context of an adenovirus. This work was funded in part by European Union Horizon 2020 research and innovation programme, Marie-Sklodowska-Curie grant number 643130.
A recombinant replication competent adenovirus comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, wherein the replication competent adenovirus comprises a modification that enables preferential replication of the adenovirus in tumor cells, and wherein the modification comprises:
A method for enhancing the rate of replication of a recombinant replication competent adenovirus in a permissive cell comprising providing the genome of said adenovirus with a coding sequence for a GSK3 protein operably linked to an expression control sequence for expressing said coding sequence in said cell, wherein the replication competent adenovirus comprises a modification that enables preferential replication of the adenovirus in tumor cells, and wherein the modification comprises:
A method for increasing an oncolytic property of an oncolytic recombinant replication competent adenovirus comprising providing the genome of said adenovirus with coding sequence for a GSK3 protein operably linked to an expression control sequence for expressing said coding sequence, wherein the replication competent adenovirus comprises a modification that enables preferential replication of the adenovirus in tumor cells, and wherein the modification comprises:
A method of increasing the rate of replication and spreading of a recombinant replication competent adenovirus in a tumor, the method comprising providing the oncolytic adenovirus with a coding sequence for a GSK3 protein operably linked to an expression control sequence for expressing said coding sequence in cells of said tumor, wherein the replication competent adenovirus comprises a modification that enables preferential replication of the adenovirus in tumor cells, and wherein the modification comprises:
Dependencies are inferred from the claim text.